Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
AstraZeneca
Mallinckrodt
Moodys
McKinsey

Last Updated: August 17, 2022

EVEKEO ODT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Evekeo Odt patents expire, and what generic alternatives are available?

Evekeo Odt is a drug marketed by Azurity and is included in one NDA. There are three patents protecting this drug.

The generic ingredient in EVEKEO ODT is amphetamine sulfate. There are fifty-five drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the amphetamine sulfate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Evekeo Odt

A generic version of EVEKEO ODT was approved as amphetamine sulfate by AMNEAL PHARMS on September 26th, 2018.

  Try it Free

Summary for EVEKEO ODT
Drug patent expirations by year for EVEKEO ODT
Drug Prices for EVEKEO ODT

See drug prices for EVEKEO ODT

Pharmacology for EVEKEO ODT

US Patents and Regulatory Information for EVEKEO ODT

EVEKEO ODT is protected by three US patents.

Patents protecting EVEKEO ODT

Taste-masked pharmaceutical compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Oral amphetamine composition
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing


Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Azurity EVEKEO ODT amphetamine sulfate TABLET, ORALLY DISINTEGRATING;ORAL 209905-005 Apr 16, 2021 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Azurity EVEKEO ODT amphetamine sulfate TABLET, ORALLY DISINTEGRATING;ORAL 209905-002 Jan 30, 2019 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Azurity EVEKEO ODT amphetamine sulfate TABLET, ORALLY DISINTEGRATING;ORAL 209905-001 Jan 30, 2019 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Azurity EVEKEO ODT amphetamine sulfate TABLET, ORALLY DISINTEGRATING;ORAL 209905-003 Jan 30, 2019 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Harvard Business School
Merck
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.